This proposed 3-arm randomized study will compare different pharmacy based approaches that include HIV prevention medication (PrEP and PEP), routine STI testing, and preventive antibiotic (doxycycline) for STIs. The study will assess how well these services can be implemented, how acceptable they are to young women, and whether they are cost-effective.
Cis-gender female
Seeking contraception (emergency contraception, oral contraceptive pills, injectables, implants, and condoms) from the retail pharmacy site
Age ≥ 15 and <25 years old
Willingness to receive PrEP screening per national guidelines including HIV testing
Current participation in other ongoing studies.
Medical contraindications to PrEP or doxycycline use (e.g., severe allergy to doxycycline, serious hepatic or renal disease).
Any other condition that, in the investigator's judgment, would make participation unsafe or interfere with study procedures.
University of Washington
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborator
National Institutes of Health (NIH)
Collaborator